Sidley represented Shandong Weigao Group Medical Polymer Company Limited (HKEX: 1066, Shandong Weigao Group) on the successful signing of the loan agreements with International Finance Corporation, a member of the World Bank Group and the largest global development institution focused on the private sector in developing countries (“IFC”), pursuant to which loans with an aggregated principal amount of up to US$250 million (equivalent to approximately HK$1.95 billion) will be made available to the Borrowers, a wholly owned subsidiary of the Company.
The successful signing of loan agreements marked a significant milestone for Shandong Weigao Group, demonstrating its ability to secure long-term substantial financing for its strategic initiatives and operations.
Shandong Weigao Group is a medical device company in China, principally engaged in the research and development, production, and sale of single-use medical devices. Shandong Weigao Group is recognised as an industrialization base to commercialise products developed by the State High-tech Research and Development (863) Program, the State High-tech Enterprise, and the State Technology Center.
The Sidley team was led by partner Olivia Ngan (Hong Kong). Other team members included senior managing associates Dora Pan (Beijing) and Horine Ye (Hong Kong).
Sidley’s banking and finance team in Hong Kong is part of the multidisciplinary China Corporate and Finance group. The team has been ranked as “Leading International Firm in Banking & Finance” by Chambers Greater China Region 2024, “Leading Firm: Banking and Finance in Hong Kong” by The Legal 500 Asia Pacific 2023–2025, and “Firm of the Year: Banking and Finance” at the China Business Law Awards 2023. The team has received a number of accolades by independent organizations including The Asset and IFLR Asia-Pacific Awards.
